Spring Bank Announces FDA Acceptance of IND Application for SB 11285, an IV-Administered STING Agonist, for the Treatment of Advanced Solid Tumors

NEXT STORY
Turning Point Therapeutics Appoints Biotechnology Investment Banker Yi Larson as Executive Vice President and Chief Financial Officer
PREV STORY
Plus Therapeutics, Inc. Announces Nasdaq Ticker Symbol Changes and Reverse Stock Split
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Asterias Biotherapeutics Announces Closing of $10.4 Million Registered Direct Offering

FREMONT, Calif., Oct. 19, 2017 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American:AST), a ...

author_avatar
NASDAQ Market News

OncBioMune Phase 2 Clinical Trial to Begin Enrollment; Company Announces Other Developments and Corporate Milestones

BATON ROUGE, La., Nov. 08, 2018 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" ...

author_avatar
NASDAQ Market News

Immunicum AB: Invitation to Investor Event

Press Release 24 May 2018 Immunicum AB: Invitation to Investor Event Immunicum AB (publ; ...

author_avatar
NASDAQ Market News